Status Epilepticus Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Marinus Pharma, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire

Posted on
by

Status Epilepticus Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Marinus Pharma, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire
The Key Status Epilepticus Companies in the market include – Marinus Pharmaceuticals, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire, and others.

 

DelveInsight’s “Status Epilepticus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Status Epilepticus, historical and forecasted epidemiology as well as the Status Epilepticus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Status Epilepticus, offering comprehensive insights into the Status Epilepticus revenue trends, prevalence, and treatment landscape. The report delves into key Status Epilepticus statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Status Epilepticus therapies. Additionally, we cover the landscape of Status Epilepticus clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Status Epilepticus treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Status Epilepticus space.

 

To Know in detail about the Status Epilepticus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Status Epilepticus Market Forecast

 

Some of the key facts of the Status Epilepticus Market Report:

  • The Status Epilepticus market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In October 2024, Marinus Pharmaceuticals announced findings from the pivotal Phase III RAISE trial evaluating intravenous (IV) ganaxolone for refractory status epilepticus (RSE). The trial successfully met one of its two co-primary endpoints, demonstrating a notable impact on seizure cessation in RSE patients.

  • Key Status Epilepticus Companies: Marinus Pharmaceuticals, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire, and others

  • Key Status Epilepticus Therapies: Ganaxolone, Lorazepam, Staccato alprazolam, IV Ganaxolone active, SAGE-547, SHP615, and othes.

  • Research by Manuel Garcia-Ruiz et al. (2024) in Spain indicated that 23–48% of status epilepticus patients progress to refractory status epilepticus (RSE), while 22% develop super-refractory status epilepticus (SRSE). Both conditions were linked to high morbidity and mortality rates.

  • The Status Epilepticus market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Status Epilepticus pipeline products will significantly revolutionize the Status Epilepticus market dynamics.

  • A study by Mevius and Joeres (2023) found that the incidence of status epilepticus in Germany was 25.5 cases per 100,000 individuals. The occurrence was slightly higher in males at 25.69 per 100,000, compared to 25.39 per 100,000 in females.

  • According to research by Lu and Faure (2020), the annual incidence of status epilepticus in the U.S. ranges between 18.3 and 41 cases per 100,000 individuals. This figure is expected to increase at a notable compound annual growth rate (CAGR) over the forecast period from 2024 to 2034.

 

Status Epilepticus Overview

Status Epilepticus is a serious and life-threatening neurological condition where a seizure lasts longer than 5 minutes or multiple seizures occur without full recovery between them. It requires immediate medical intervention to prevent brain damage, respiratory failure, or death.

It can be triggered by epilepsy, stroke, infections, head injuries, or medication withdrawal. Treatment involves intravenous antiepileptic drugs like benzodiazepines (lorazepam, diazepam) and supportive care to stabilize the patient. Prompt treatment is crucial to prevent long-term complications.

 

Get a Free sample for the Status Epilepticus Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/status-epilepticus-market

 

Status Epilepticus Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Status Epilepticus Epidemiology Segmentation:

The Status Epilepticus market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Status Epilepticus

  • Prevalent Cases of Status Epilepticus by severity

  • Gender-specific Prevalence of Status Epilepticus

  • Diagnosed Cases of Episodic and Chronic Status Epilepticus

 

Download the report to understand which factors are driving Status Epilepticus epidemiology trends @ Status Epilepticus Epidemiology Forecast

 

Status Epilepticus Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Status Epilepticus market or expected to get launched during the study period. The analysis covers Status Epilepticus market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Status Epilepticus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Status Epilepticus Therapies and Key Companies

  • Ganaxolone: Marinus Pharmaceuticals

  • Lorazepam: Pfizer

  • Staccato alprazolam: UCB Biopharma SRL

  • IV Ganaxolone active: Marinus Pharmaceuticals

  • SAGE-547: Sage Therapeutics

  • SHP615: Shire

 

Discover more about therapies set to grab major Status Epilepticus market share @ Status Epilepticus Treatment Landscape

 

Status Epilepticus Market Drivers

  • Rising Prevalence of Epilepsy & Neurological Disorders

  • Advancements in Treatment Options

  • Growing Awareness & Early Diagnosis

  • Government & Private Sector Initiatives

  • Technological Innovations in Drug Delivery

 

Status Epilepticus Market Barriers

  • High Treatment Costs

  • Adverse Effects of Antiepileptic Drugs

  • Delayed Diagnosis & Treatment

  • Regulatory Challenges & Drug Approval Delays

 

Scope of the Status Epilepticus Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Status Epilepticus Companies: Marinus Pharmaceuticals, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire, and others

  • Key Status Epilepticus Therapies: Ganaxolone, Lorazepam, Staccato alprazolam, IV Ganaxolone active, SAGE-547, SHP615, and others

  • Status Epilepticus Therapeutic Assessment: Status Epilepticus current marketed and Status Epilepticus emerging therapies

  • Status Epilepticus Market Dynamics: Status Epilepticus market drivers and Status Epilepticus market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Status Epilepticus Unmet Needs, KOL’s views, Analyst’s views, Status Epilepticus Market Access and Reimbursement

 

To know more about Status Epilepticus companies working in the treatment market, visit @ Status Epilepticus Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Status Epilepticus Market Report Introduction

2. Executive Summary for Status Epilepticus

3. SWOT analysis of Status Epilepticus

4. Status Epilepticus Patient Share (%) Overview at a Glance

5. Status Epilepticus Market Overview at a Glance

6. Status Epilepticus Disease Background and Overview

7. Status Epilepticus Epidemiology and Patient Population

8. Country-Specific Patient Population of Status Epilepticus

9. Status Epilepticus Current Treatment and Medical Practices

10. Status Epilepticus Unmet Needs

11. Status Epilepticus Emerging Therapies

12. Status Epilepticus Market Outlook

13. Country-Wise Status Epilepticus Market Analysis (2019–2032)

14. Status Epilepticus Market Access and Reimbursement of Therapies

15. Status Epilepticus Market Drivers

16. Status Epilepticus Market Barriers

17. Status Epilepticus Appendix

18. Status Epilepticus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/